Back to Results

Impact Biomedical Inc (IBO)

Impact Biomedical Inc. is a Houston-based healthcare company focused on discovering, developing, and commercializing products and technologies aimed at unmet needs in human health and wellness. The company’s work spans specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. Its pipeline includes Linebacker, a small-molecule platform based on electrophilically enhanced polyphenol compounds with applications in oncology, inflammatory disorders, and neurology; Laetose, a sugar-and-inositol technology designed to affect inflammatory and metabolic responses; and Equivir/Equivir G, a polyphenol-based blend being developed for potential antiviral use in supplements and medications. Impact Biomedical is also developing functional fragrance formulations with botanical ingredients for antimicrobial and other consumer applications. The company was incorporated in 2018 and operates as a subsidiary of DSS BioHealth Security, Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NYSE-IBO
$2.33
-47.2% Downside
Overvalued
Not available
Not available
Fair
0.0%
47.5x
3.5x
1,074.1x
37.593 M
40.829 M
0.0%
10.7%
-281.0
-64.2%
Valuation • Fair Value

Impact Biomedical Inc (NYSE-IBO) Fair Value by Valuation Model

Review the available estimates for Impact Biomedical Inc (NYSE-IBO), including Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$2.33

Estimated downside of 47.2% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

Ben Graham Formula Value

$1.03

Classic Ben Graham valuation formula reference.

Comps Fair Value

$2.33

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 4 available valuation references for Impact Biomedical Inc (NYSE-IBO) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Impact Biomedical Inc (NYSE-IBO)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

35 K

Current operating scale indicator.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-3.952 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Impact Biomedical Inc (NYSE-IBO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Impact Biomedical Inc (NYSE-IBO)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

6

Mid-range quality score.

Altman Z-Score

-281.0

Lower score that deserves closer risk review.

FCF / Net Income

-64.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Impact Biomedical Inc (NYSE-IBO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Impact Biomedical Inc (NYSE-IBO)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Impact Biomedical Inc (NYSE-IBO). No upcoming dividend amount or event date is currently available.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Impact Biomedical Inc (NYSE-IBO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Impact Biomedical Inc (NYSE-IBO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Impact Biomedical Inc (NYSE-IBO) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Impact Biomedical Inc (NYSE-IBO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Impact Biomedical Inc (NYSE-IBO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Impact Biomedical Inc (NYSE-IBO) Stock FAQ

Data-supported answers about Impact Biomedical Inc (NYSE-IBO), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.33
Estimated downside 47.2%
Valuation Rating
Overvalued
Estimated downside of 47.2%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Impact Biomedical Inc (NYSE-IBO) is $2.33. This implies an estimated downside of 47.2% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 47.2% versus the current market price.

The current financial health read for Impact Biomedical Inc (NYSE-IBO) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Impact Biomedical Inc (NYSE-IBO).

The current P/E ratio listed for Impact Biomedical Inc (NYSE-IBO) is 47.5x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Impact Biomedical Inc is 37.593 M.

The current enterprise value listed for Impact Biomedical Inc is 40.829 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Impact Biomedical Inc is NYSE-IBO, and the stock is listed on NYSE.

Impact Biomedical Inc (NYSE-IBO) is listed on NYSE.

The current debt-to-total-capital ratio listed for Impact Biomedical Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Impact Biomedical Inc is 10.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NYSE

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,215.6 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 655.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.2 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 310 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 179.5 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 170.3 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 129 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 113.6 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 69.723 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 48.75 B
HLN NYSE HALEON PLC ADR Fair Value Undervalued Market Cap 40.368 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 38.751 B
ZTS NYSE Zoetis Inc Fair Value Undervalued Market Cap 33.93 B
VTRS NASDAQ Viatris Inc Fair Value Fair Market Cap 21.789 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Undervalued Market Cap 14.59 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 11.996 B
ELAN NYSE Elanco Animal Health Fair Value Overvalued Market Cap 11.831 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 7.834 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Undervalued Market Cap 6.827 B